Abstract: The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY 1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).
Abstract: Disclosed herein are a method for improving cognition in an individual having findings consistent with a cognitive impairment, and a method of enhancing cognition in an individual. The methods include administering a therapeutically effective amount of (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a metabolite or a pharmaceutically acceptable salt thereof to the individual.
Abstract: This application relates to a method of treatment with tradipitant, and more particularly, to a method of treatment of pruritus with tradipitant.
Type:
Grant
Filed:
July 31, 2020
Date of Patent:
May 10, 2022
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
March 29, 2022
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: The present invention relates to the selection of patients with enhanced antipsychotic treatment efficacy with iloperidone based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to treatment of such patients based upon the identification of their genetic information.
Type:
Grant
Filed:
August 16, 2019
Date of Patent:
January 4, 2022
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Mihael H. Polymeropoulos, Sandra Smieszek
Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Type:
Grant
Filed:
September 30, 2020
Date of Patent:
December 21, 2021
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
Type:
Grant
Filed:
February 25, 2020
Date of Patent:
October 12, 2021
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
January 4, 2019
Date of Patent:
August 17, 2021
Assignee:
VANDA PHARMACEUTICALS INC
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
August 3, 2021
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
Type:
Grant
Filed:
September 12, 2008
Date of Patent:
July 13, 2021
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Christian Lavedan, Mihael H. Polymeropoulos, Gunther Birznieks
Abstract: Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof. In one embodiment, the invention provides a method of preventing schizophrenic relapse in an individual diagnosed with schizophrenia, the method comprising: administering to the individual iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof at a daily dose between about 12 mg and about 16 mg following a period in which the individual's schizophrenia was stabilized.
Type:
Grant
Filed:
September 6, 2019
Date of Patent:
April 27, 2021
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Mihael H. Polymeropoulos, Curt D. Wolfgang
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
February 16, 2020
Date of Patent:
April 20, 2021
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
September 14, 2019
Date of Patent:
March 16, 2021
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Type:
Grant
Filed:
February 25, 2020
Date of Patent:
November 10, 2020
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
Abstract: Disclosed herein is a method of treating or preventing motion sickness or at least one symptom thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant.